Are GLP-1, GIP, and Glucagon Weight-Loss Drugs Really a Silver Bullet? A Hunger Biology Perspective

What the researchers found

This perspective article argues that while mono, dual, and triple agonists of GLP-1, GIP, and glucagon receptors produce impressive weight loss, fundamental biological principles about hunger and satiety raise important questions that go beyond currently reported side effects. The authors contend that suppressing hunger through pharmacology does not bypass the complex goal-oriented behaviors, systemic metabolism, and cellular metabolic processes that govern how the body regulates energy balance. They caution against treating these drugs as a simple silver bullet for obesity without understanding the deeper biological implications of overriding the hunger-satiety system.

Why it matters

As GLP-1-based obesity drugs become among the most widely prescribed medications in history, this perspective serves as a scientific counterweight to uncritical enthusiasm. The authors highlight that appetite regulation involves deeply interconnected systems — from cellular metabolism to complex behaviors — and that pharmacologically suppressing hunger may have consequences we don't yet fully understand. These are important considerations as dual and triple agonists push weight loss even further.

How the study worked

This is a perspective article reflecting on the biology of hunger and satiety in the context of incretin-based obesity therapies. It synthesizes existing knowledge about GLP-1, GIP, and glucagon receptor signaling rather than presenting original experimental data.

Who was studied

Not applicable — this is a perspective article, not an empirical study

What this study cannot tell us

As a perspective piece, this article presents the authors' viewpoint rather than systematic evidence. It does not perform a structured review or meta-analysis of the existing literature. The concerns raised are theoretical and biological in nature, not backed by new clinical data demonstrating specific harms.

How to read the evidence

This is a perspective article presenting expert opinion and biological reasoning, not original data or systematic review. It is valuable for framing questions and provoking critical thinking, but does not constitute empirical evidence.

When this study was published

Published in 2024, this perspective is timely and directly relevant to the current explosion of interest in incretin-based obesity therapies, including tirzepatide and emerging triple agonists like retatrutide.

The bigger picture

The explosive growth of GLP-1-based obesity drugs has created a narrative of pharmacological triumph over weight gain. This perspective pushes back by asking what happens when you pharmacologically override a system that evolved over millions of years to keep organisms alive. As the field moves from single-agonist drugs (semaglutide) to dual (tirzepatide) and triple agonists (retatrutide), the question of long-term biological consequences becomes increasingly urgent.

Questions still open

• What are the long-term metabolic consequences of chronically suppressing hunger through GLP-1/GIP/glucagon receptor agonism?
• Does pharmacological appetite suppression lead to compensatory changes in cellular metabolism or energy-seeking behaviors over time?
• How do dual and triple agonists differ from single-target drugs in their effects on the brain's hunger-satiety circuitry?

Common questions

Read the original research

GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective.

Endocrinology, 165(11)

Citation

D'Ávila, Mateus; Hall, Samantha; Horvath, Tamas L. (2024). GLP-1, GIP, and Glucagon Agonists for Obesity Treatment: A Hunger Perspective.. Endocrinology, 165(11). https://doi.org/10.1210/endocr/bqae128